The PR’s this week made me wince. I understand how some feel it was a way to get word out about RVX and a possible COVID -19 connection, but as certain posters noted, to me it just wreaked of desperation and amateurism.

COVID -19 has killed in progress deals everywhere. Many jumped on Dutchfella for his comments last week that he had some hope for a potential transaction of some type in April. I have followed him for years on boards and he is well respected – at least as far as someone on an anonymous board can be. Not saying he would never post something that would benefit him, I don’t know him enough to confirm or deny that. But just saying, I would not be surprised there was a grain or two of truth about a potential discussion that was derailed by COVID.

Let’s assume there was a potential deal/partnership that feel apart due to the virus; where does that leave RVX? Essentially with no money to carry on, no money to keep trials going and in limbo. This is obviously a simplistic statement in a complicated situation, but it may be accurate to some degree.

Thus, in the near term, that means just covering reduced month to month costs with small exempt distributions, keeping creditors at bay with the rest of the world and waiting for Big Pharma to decide it is time to return to the growing their companies by partnership or takeout. The question is, if this happens, how does RVX holdout and not give in to a very low offer? At some-point Hepa is going to want to move on in some manner and Dart probably does not spend more than a minute a week worrying about RVX.

So, if I am anywhere close to the truth and I may be so far out in leftfield I am in the bleachers. RVX will likely in the next 3-6 months have to hold their nose on a deal/partnership that is based on future performance more than upfront payment and move on. The current apparent situation cannot go on infinitum. Hope I am wrong.